Compare STTK & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | RMNI |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 383.7M |
| IPO Year | 2020 | 2015 |
| Metric | STTK | RMNI |
|---|---|---|
| Price | $4.53 | $5.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $15.40 | $7.17 |
| AVG Volume (30 Days) | ★ 841.6K | 509.7K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 197.50 |
| EPS | N/A | ★ 0.11 |
| Revenue | $1,000,000.00 | ★ $431,496,000.00 |
| Revenue This Year | N/A | $5.92 |
| Revenue Next Year | $14.28 | $5.90 |
| P/E Ratio | ★ N/A | $49.45 |
| Revenue Growth | N/A | ★ 5.33 |
| 52 Week Low | $1.89 | $2.87 |
| 52 Week High | $8.33 | $5.68 |
| Indicator | STTK | RMNI |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 59.44 |
| Support Level | $4.38 | $3.17 |
| Resistance Level | $7.66 | $5.68 |
| Average True Range (ATR) | 0.39 | 0.29 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.92 | 59.26 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.